Immunovant Inc. (IMVT)
17.13
-1.24 (-6.75%)
At close: Mar 31, 2025, 3:59 PM
17.09
-0.20%
After-hours: Mar 31, 2025, 04:36 PM EDT
Company Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia.
The company was incorporated in 2018 is headquartered in New York, New York.
Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Immunovant Inc.
| Country | United States |
| IPO Date | Jun 21, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 207 |
| CEO | Dr. Peter Salzmann M.B.A., M.D. |
Contact Details
Address: 320 West 37th Street New York, New York United States | |
| Website | https://immunovant.com |
Stock Details
| Ticker Symbol | IMVT |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001764013 |
| CUSIP Number | 45258J102 |
| ISIN Number | US45258J1025 |
| Employer ID | 83-2771572 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter Salzmann M.B.A., M.D. | Chief Executive Officer & Director |
| Christopher A. Van Tuyl Esq., J.D. | Chief Legal Officer & Corporate Secretary |
| Dr. Jay S. Stout Ph.D. | Chief Technology Officer |
| Eva Renee Barnett M.B.A. | Chief Financial Officer |
| Melanie Gloria B.S.N. | Chief Operating Officer |
| Andy Deig | Senior Vice President of Strategic Finance |
| Christine Blodgett | Senior Vice President of Human Resources |
| Dr. Frank M. Torti M.B.A., M.D. | Executive Chairperson of the Board |
| Dr. Michael Geffner M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Lauren Schrier M.B.A. | Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2025 | SCHEDULE 13G | Filing |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 11, 2025 | 4 | Filing |
| Mar 07, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 21, 2025 | 4 | Filing |
| Feb 21, 2025 | 4 | Filing |
| Feb 21, 2025 | 4 | Filing |
| Feb 06, 2025 | 10-Q | Quarterly Report |
| Feb 06, 2025 | 8-K | Current Report |
| Jan 24, 2025 | 8-K | Current Report |